ARCH Venture Partners Archives

Karuna Therapeutics adds Dr Heather Preston to Board along with raising $68m Series B financing led by ARCH Venture Partners

December 3, 2020March 18, 2019

– USA, MA – Karuna Therapeutics, Inc., focused on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders including psychosis in schizophrenia, psychosis in Alzheimer’s disease, and pain, today announced the completion of a $68 million Series B financing round, including the issuance of $5 million in shares upon conversion of debt into equity.…

Gossamer Bio presents its Board of Directors along with raising $100m financing co-led by ARCH Venture Partners and Omega Funds

November 30, 2023January 6, 2018

– USA, CA – Gossamer Bio, Inc., a new biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products to address high unmet needs of targeted patient populations has announced today its launch by Receptos’ former executive leadership team, Faheem Hasnain and Sheila Gujrathi, M.D.…

eGenesis adds Daniel Lynch to its Board as Executive Chairman along with raising $38m Series A financing led by Biomatics Capital and ARCH Venture Partners

March 8, 2021March 15, 2017

– USA, MA – eGenesis, a biotechnology company focused on utilizing genome editing technology to make xenotransplantation a routine and lifesaving medical procedure, today announced that it raised a $38 million Series A financing co-led by Biomatics Capital and ARCH Venture Partners, with participation from Khosla Ventures, Alta Partners, Alexandria Venture Investments, Heritage Provider Network, Berggruen Holdings North America Ltd.,…

Vividion Therapeutics announces Dr Tom Daniel to its Board as Executive Chairman along with raising $50m Series A financing

November 30, 2020February 2, 2017

– USA, CA – Vividion Therapeutics, Inc., a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome-wide ligand and target discovery, has been launched today.…

Nohla Therapeutics appoints Katie Fanning to its Board of Directors as CEO

February 3, 2017February 2, 2017

– USA, WA – Nohla Therapeutics Inc. , a leading developer of universal donor cellular therapies for the treatment of patients with life threatening hematological malignancies, announced today the appointment of Kathleen Fanning as President and Chief Executive Officer and an Executive member of the Board of Directors.…